Albumin Stimulates the Activity of the Human UDP-Glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the Effects Are Enzyme and Substrate Dependent

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Manevski, Nenad ^a   Troberg, Johanna ^a   Svaluto Moreolo, Paolo ^a   Dziedzic, Klaudyna ^a,b   Yli Kauhaluoma, Jari ^a   Finel, Moshe ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHOL; 17ALPHA ESTRADIOL; 6 HYDROXYINDOLE; BOVINE SERUM ALBUMIN; ENTACAPONE; ESTRADIOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2A1; GLUCURONOSYLTRANSFERASE 2B15; HYMECROMONE; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG GLUCURONIDATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIPOPHILICITY; MICHAELIS MENTEN KINETICS; NONHUMAN;

ANIMALS; CATTLE; ENZYME ACTIVATION; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; KINETICS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN, BOVINE; SUBSTRATE SPECIFICITY;

BOVINAE;

EID: 84872764713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054767     Document Type: Article

References (43)

1. Guillemette C, Levesque E, Harvey M, Bellemare J, Menard V, (2010) UGT genomic diversity: Beyond gene duplication. Drug Metabolism Reviews 42: 24-44.
2. Miners JO, Mackenzie PI, Knights KM, (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metabolism Reviews 42: 189-201.
3. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, et al. (2010) ABCC2/Abcc2: A multispecific transporter with dominant excretory functions. Drug Metabolism Reviews 42: 402-436.
4. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, et al. (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: The effect of fluconazole on zidovudine glucuronidation. British Journal of Clinical Pharmacology 61: 427-439.
5. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, et al. (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: Implications for in vitro-in vivo extrapolation. The Journal of Pharmacology and Experimental Therapeutics 321: 137-147.
6. Rowland A, Knights KM, Mackenzie PI, Miners JO, (2008) The "albumin effect" and drug glucuronidation: Bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metabolism and Disposition 36: 1056-1062.
7. Shiraga T, Yajima K, Suzuki K, Suzuki K, Hashimoto T, et al. (2012) Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor xa inhibitor, in human liver and intestine. Drug Metabolism and Disposition 40: 276-282.
8. Manevski N, Moreolo PS, Yli-Kauhaluoma J, Finel M, (2011) Bovine serum albumin decreases km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases vmax values of UGT1A9. Drug Metabolism and Disposition 39: 2117-2129.
9. Manevski N, Yli-Kauhaluoma J, Finel M, (2012) UDP-glucuronic acid binds first and the aglycone substrate binds second to form a ternary complex in UGT1A9-catalyzed reactions, in both the presence and absence of bovine serum albumin. Drug Metabolism and Disposition 40: 2192-2203.
10. Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, et al. (2012) Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: Altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metabolism and Disposition 40: 1051-1065.
11. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, et al. (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metabolism and Disposition 34: 1055-1062.
12. Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, et al. (2010) In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. The Journal of Pharmacology and Experimental Therapeutics 334: 609-618.
13. Luukkanen L, Kilpelainen I, Kangas H, Ottoila P, Elovaara E, et al. (1999) Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides. Bioconjugate Chemistry 10: 150-154.
14. Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, et al. (2007) Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenetics and Genomics 17: 115-126.
15. Zhang H, Tolonen A, Rousu T, Hirvonen J, Finel M, (2011) Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in caco-2 cells. Drug Metabolism and Disposition 39: 456-464.
16. Kaivosaari S, Toivonen P, Aitio O, Sipilä J, Koskinen M, et al. (2008) Regio- and stereospecific N-glucuronidation of medetomidine: The differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metabolism and Disposition 36: 1529-1537.
17. Little JM, Lehman PA, Nowell S, Samokyszyn V, Radominska A, (1997) Glucuronidation of all-trans-retinoic acid and 5,6-epoxy-all-trans-retinoic acid. activation of rat liver microsomal UDP-glucuronosyltransferase activity by alamethicin. Drug Metabolism and Disposition 25: 5-11.
18. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA, (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition 28: 560-566.
19. Kurkela M, Hirvonen J, Kostiainen R, Finel M, (2004) The interactions between the N-terminal and C-terminal domains of the human UDP-glucuronosyltransferases are partly isoform-specific, and may involve both monomers. Biochemical Pharmacology 68: 2443-2450.
20. Motulsky H, Christopoulos A (2004) Fitting models to biological data using linear and nonlinear regression: A practical guide to curve fitting. New York, USA: Oxford University Press.
21. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, et al. (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37: 4137-4147.
22. Houston JB, Kenworthy KE, (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical michaelis-menten model. Drug Metabolism and Disposition 28: 246-254.
23. Taylor JR (1996) An introduction to error analysis: The study of uncertainties in physical measurements. Sausalito, California, USA: University Science Books.
24. Itäaho K, Mackenzie PI, Ikushiro S, Miners JO, Finel M, (2008) The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metabolism and Disposition 36: 2307-2315.
25. Rowland A, Knights KM, Mackenzie PI, Miners JO, (2009) Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): Potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metabolism and Disposition 37: 1395-1403.
26. Shareef A, Angove M, Wells J, Johnson B, (2006) Aqueous solubilities of estrone, 17 beta-estradiol, 17 alpha-ethynylestradiol, and bisphenol A. Journal of Chemical and Engineering Data. 51: 879-881.
27. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, et al. (2004) Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metabolism and Disposition 32: 413-423.
28. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, et al. (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Molecular Pharmacology 74: 1152-1162.
29. Zhou J, Tracy TS, Remmel RP, (2010) Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: Evidence for multiple UGT1A4 aglycone binding sites. Drug Metabolism and Disposition 38: 431-440.
30. Zhou J, Tracy TS, Remmel RP, (2011) Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metabolism and Disposition 39: 322-329.
31. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, et al. (2005) Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metabolism and Disposition 33: 1017-1026.
32. Lautala P, Ethell BT, Taskinen J, Burchell B, (2000) The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metabolism and Disposition 28: 1385-1389.
33. Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A, (2009) Prediction of drug clearance by glucuronidation from in vitro data: Use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metabolism and Disposition 37: 82-89.
34. Gill KL, Houston JB, Galetin A, (2012) Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: Comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metabolism and Disposition 40: 825-835.
35. Knights KM, Bowalgaha K, Miners JO, (2010) Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: A potential drug interaction. Drug Metabolism and Disposition 38: 1011-1014.
36. Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, Knights KM, (2011) Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: Application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metabolism and Disposition 39: 644-652.
37. Sneitz N, Court MH, Zhang X, Laajanen K, Yee KK, et al. (2009) Human UDP-glucuronosyltransferase UGT2A2: CDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A. Pharmacogenetics and Genomics 19: 923-934.
38. Turgeon D, Chouinard S, Belanger P, Picard S, Labbe JF, et al. (2003) Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases. Journal of Lipid Research 44: 1182-1191.
39. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, et al. (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): Kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochemical Pharmacology 67: 191-199.
40. Marheineke K, Grunewald S, Christie W, Reilander H, (1998) Lipid composition of Spodoptera frugiperda (Sf9) and Trichoplusia ni (tn) insect cells used for baculovirus infection. FEBS Letters 441: 49-52.
41. Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, et al. (2012) Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: Impact on in vitro-in vivo extrapolation of drug clearance. Drug Metabolism and Disposition 40: 982-989.
42. Loureiro AI, Fernandes-Lopes C, Bonifacio MJ, Wright LC, Soares-da-Silva P, (2011) Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metabolism and Disposition 39: 1486-1494.
43. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Miners JO, (2008) The "albumin effect" and in vitro-in vivo extrapolation: Sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metabolism and Disposition 36: 870-877.